[Not Available].
作者信息
Llover Mariona Nadal, Jiménez Montse Cols
机构信息
Responsable de Farmacia. Àmbit d'Atenció Primària Girona: Institut Català de la Salut Girona, España.
Responsable de Farmacia de Atención Primaria. Serveis de Salut Integrats Baix Empordà, Girona, España.
出版信息
FMC. 2021 Jan;28(1):40-56. doi: 10.1016/j.fmc.2020.10.005. Epub 2021 Jan 23.
Abstract
摘要
相似文献
1
[Not Available].[无可用内容]
FMC. 2021 Jan;28(1):40-56. doi: 10.1016/j.fmc.2020.10.005. Epub 2021 Jan 23.
引用本文的文献
1
SARS-CoV-2 and gastrointestinal diseases.严重急性呼吸综合征冠状病毒2与胃肠道疾病。
Front Microbiol. 2023 May 30;14:1177741. doi: 10.3389/fmicb.2023.1177741. eCollection 2023.
2
Mortality and Survival Factors in Patients with Moderate and Severe Pneumonia Due to COVID-19.新型冠状病毒肺炎所致中重度肺炎患者的死亡率及生存因素
Healthcare (Basel). 2023 Mar 23;11(7):932. doi: 10.3390/healthcare11070932.
3
Convalescent Plasma Therapy, Therapeutic Formulations of Repurposed Drugs in 20th Century Epidemics against COVID-19: A Systematic Review.20世纪针对COVID-19疫情的恢复期血浆疗法及药物重新利用的治疗配方：一项系统评价
Pharmaceutics. 2022 May 9;14(5):1020. doi: 10.3390/pharmaceutics14051020.
4
Antiviral Therapeutic Approaches for SARS-CoV-2 Infection: A Systematic Review.2019冠状病毒病感染的抗病毒治疗方法：一项系统评价
Pharmaceuticals (Basel). 2021 Jul 28;14(8):736. doi: 10.3390/ph14080736.
5
Antiviral Activity of Metabolites from Peruvian Plants against SARS-CoV-2: An In Silico Approach.抗 SARS-CoV-2 的秘鲁植物代谢产物的抗病毒活性：一种计算机模拟方法。
Molecules. 2021 Jun 25;26(13):3882. doi: 10.3390/molecules26133882.
本文引用的文献
1
Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.用于治疗新冠肺炎的抗病毒药物 repurposed - 世界卫生组织团结试验中期结果
N Engl J Med. 2021 Feb 11;384(6):497-511. doi: 10.1056/NEJMoa2023184. Epub 2020 Dec 2.
2
3
Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.洛匹那韦利托那韦在因 COVID-19 住院的患者中的应用（RECOVERY）：一项随机、对照、开放标签、平台试验。
Lancet. 2020 Oct 24;396(10259):1345-1352. doi: 10.1016/S0140-6736(20)32013-4. Epub 2020 Oct 5.
4
Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19.羟氯喹治疗 COVID-19 住院患者的疗效。
N Engl J Med. 2020 Nov 19;383(21):2030-2040. doi: 10.1056/NEJMoa2022926. Epub 2020 Oct 8.
5
Immunosuppression for COVID-19: repurposing medicines in a pandemic.用于治疗新冠肺炎的免疫抑制：在大流行中重新利用药物。
Aust Prescr. 2020 Aug;43(4):106-107. doi: 10.18773/austprescr.2020.037. Epub 2020 Jun 17.
6
Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis.COVID-19 重症患者全身使用皮质类固醇与死亡率的关联：一项荟萃分析。
JAMA. 2020 Oct 6;324(13):1330-1341. doi: 10.1001/jama.2020.17023.
7
Two Fatal Cases of Acute Liver Failure Due to HSV-1 Infection in COVID-19 Patients Following Immunomodulatory Therapies.两例新冠病毒感染患者在接受免疫调节治疗后因单纯疱疹病毒1型感染导致急性肝衰竭的致命病例。
Clin Infect Dis. 2021 Jul 1;73(1):e252-e255. doi: 10.1093/cid/ciaa1246.
8
Tocilizumab in patients with severe COVID-19: a retrospective cohort study.托珠单抗治疗重症新型冠状病毒肺炎患者：一项回顾性队列研究
Lancet Rheumatol. 2020 Aug;2(8):e474-e484. doi: 10.1016/S2665-9913(20)30173-9. Epub 2020 Jun 24.
9
Drug treatments for covid-19: living systematic review and network meta-analysis.Covid-19 的药物治疗：系统评价和网络荟萃分析。
BMJ. 2020 Jul 30;370:m2980. doi: 10.1136/bmj.m2980.
10
COVID-19 and the quality use of medicines: evidence, risks and fads.2019冠状病毒病与药品合理使用：证据、风险与时尚潮流
Aust Prescr. 2020 Jun;43(3):78-80. doi: 10.18773/austprescr.2020.031. Epub 2020 May 8.
Zotero 插件